SEARCH:   Advanced

Blood, 15 August 2005, Vol. 106, No. 4, pp. 1207-1209. Prepublished online as a Blood First Edition Paper on April 28, 2005; DOI 10.1182/blood-2005-03-1183. This Article Abstract Full Text (PDF) All Versions of this Article: 2005-03-1183v1 106/4/1207    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Steensma, D. P. Articles by Tefferi, A. Search for Related Content PubMed PubMed Citation Articles by Steensma, D. P. Articles by Tefferi, A. Related Collections Neoplasia Oncogenes and Tumor Suppressors Brief Reports Clinical Trials and Observations Related Article in Blood Online Related Letters in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Brief report The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes David P. Steensma, Gordon W. Dewald, Terra L. Lasho, Heather L. Powell, Rebecca F. McClure, Ross L. Levine, D. Gary Gilliland, and Ayalew Tefferi From the Mayo Clinic and Mayo Clinic College of Medicine, Rochester, MN; and the Brigham and Women's Hospital and Harvard Medical School, Boston, MA.    Abstract Top Abstract Introduction Study design Results and discussion References   A somatic mutation in the JH2 autoinhibitory domain of the Janus kinase 2 (JAK2) tyrosine kinase was recently described in polycythemia vera, essential thrombocythemia, and myelofibrosis with myeloid metaplasia. The prevalence of this mutation in either "atypical" myeloproliferative disorders (MPDs) or the myelodysplastic syndromes (MDSs) is unknown. Bone marrow–derived genomic DNA from 245 patients—119 with chronic myelomonocytic leukemia (CMML), 101 with MDS, 11 with hypereosinophilic syndrome (HES), 8 with systemic mastocytosis (SM), and 6 with chronic neutrophilic leukemia (CNL)—was screened for the JAK2 V617F mutation. A mutant allele was detected in 11 patients: 3 with CMML (3%), 5 with MDS (5%), 2 with SM, and 1 with CNL. Interestingly, one of the patients with SM and the patient with CNL with JAK2 V617F had a history of lymphoma, and this patient with SM also had associated myelofibrosis and CMML. The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders.    Introduction Top Abstract Introduction Study design Results and discussion References   Recently, a potentially major breakthrough for understanding the pathobiology of myeloproliferative disorders (MPDs) was reported: several groups independently detected a somatic point mutation in a highly conserved residue of the pseudokinase domain of the JAK2 tyrosine kinase (V617F) in most patients with polycythemia vera (PV), as well as one-third to one-half of patients with either essential thrombocythemia (ET) or myelofibrosis with myeloid metaplasia (MMM).1-4 In the present study, we screened a large number of patients with either atypical MPD (aMPD) or myelodysplastic syndrome (MDS) to determine whether this activating JAK2 mutation is associated only with classic BCR/ABL-negative MPD,5 or if, instead, it also occurs in other chronic myeloid disorders (CMDs). In addition, we studied possible phenotypic alterations accompanying the occurrence of JAK2 V617F in these disorders. Other than chronic myeloid leukemia (CML), which is characterized by the presence of the Philadelphia chromosome or its molecular equivalent (ie, the BCR/ABL fusion oncogene, encoding a constitutively active tyrosine kinase), precise molecular definition has proven elusive for the CMD.6 In part, this is due to the mixed clonality of these disorders and the diversity of clinical presentations. Rare cases of CMML exhibit gene rearrangements involving the beta chain of the platelet-derived growth factor receptor (PDGFR) that result in cellular transformation,7 some patients with hypereosinophilic syndrome (HES) have rearrangements of the alpha chain of the PDGFR,8 and somatic activating mutations of c-KIT (eg, the recurrent D816V missense mutation) underlie a proportion of cases of SM,9 but for the majority of CMDs, a specific molecular mechanism is not yet known. The striking clinical success seen in CML therapy with pharmacologic BCR/ABL kinase inhibition by rationally designed agents including imatinib mesylate,10 AMN-107,11 and BMS-35482512 highlights the pressing need for defining comparable targets in the other CMDs. The recurrent JAK2 mutation was identified independently by a candidate gene approach1,3,4 and by high-throughput DNA sequencing of the functional domains of 85 tyrosine kinases in PV, MMM, and ET blood samples.2 In the latter analysis, JAK2 V617F was detected at the genomic DNA level in blood from 74% of 164 patients with PV, 32% of 115 patients with ET, and 35% of 46 patients with MMM who were recruited through the internet.2 Subsequent ongoing analysis of more than 250 well-characterized MPD blood and marrow samples from the Mayo Clinic CMD Cell Bank has demonstrated an even greater proportion of patients with PV, MMM, and ET with the mutation (approximately 85%, 50%, and 40%, respectively, of patients diagnosed using currently applicable screening criteria; T.L.L., D.P.S., A.T., unpublished data, March 2005). JAK2 V617F results in constitutive activation of the tyrosine kinase, phosphorylation of STAT5, and factor-independent growth of hematopoietic cells, and was not observed in blood from 209 healthy individuals, nor in buccal cells from 110 patients with PV who had the mutation in hematopoietic cells, strongly suggesting pathobiologic relevance.2 This hyperactive tyrosine kinase is an attractive target for pharmacologic inhibition, so it is important to understand how applicable such approaches might be to other myeloid disorders besides the 3 classic BCR/ABL-negative MPDs. In this study, we demonstrate that the JAK2 V617F mutation is uncommon in aCMD and MDS, despite the myeloproliferative features frequently observed in the former group; when present, it may be associated with marrow fibrosis or a history of lymphoma.    Study design Top Abstract Introduction Study design Results and discussion References   Sample collection and processing The current study was approved by the institutional review board of the Mayo Clinic, and State of Minnesota and Federal Health Insurance Portability and Accountability Act (HIPAA) guidelines regarding access to medical records were followed. Genomic DNA was obtained from 2 sources: marrow samples donated by patients to the Mayo Clinic CMD Cell Bank (MDS and aCMD except for some CMML), and methanol-preserved cultured waste cells from marrow obtained for cytogenetic studies (some CMML samples). In addition, 20 MDS DNA samples (British patients with acquired thalassemia13) and DNA from 50 healthy donors were a gift from Professor Doug Higgs (Weatherall Institute of Molecular Medicine, Oxford, United Kingdom). Other than these latter samples, all cases were reviewed by Mayo Clinic hematopathologists and diagnoses assigned according to standard World Health Organization (WHO) criteria.14 Patient characteristics are summarized in Table 1. Granulocytes were isolated from marrow samples by density centrifugation with Ficoll-Hypaque (Sigma Chemical, Saint Louis, MO). Genomic DNA was extracted using High Pure PCR Template Preparation Kit (Roche Diagnostics, Penzberg, Germany). View this table: [in this window] [in a new window]   Table 1.. Patient characteristics   JAK2 mutation analysis Genomic DNA was amplified by polymerase chain reaction (PCR), and successful amplification was confirmed by electrophoresis on an ethidium bromide–impregnated 1% agarose gel. Each 50-µL PCR reaction contained approximately 25 ng DNA template, 5 µL 10x Roche buffer (final concentration of MgCl2: 1.5 mM), 1.5 U Taq polymerase (Roche), 0.8 mM deoxynucleoside triphosphates (dNTPs; Roche), and 20 pM each of sense and antisense primers (5'-TGCTGAAAGTAGGAGAAAGTGCAT-3' and 5'-TCCTACAGTGTTTTCAGTTTCAA-3', respectively). PCR cycling parameters were: one cycle of 94°C for 2 minutes; 35 cycles of 94°C for 30 seconds, 52°C for 40 seconds, and 72°C for 40 seconds; followed by one cycle of 72°C for 2 minutes. View larger version (23K): [in this window] [in a new window]   Figure 1.. JAK2 V617F mutations. Fluorescent dye chemistry sequencing chromatograms showing homozoygous (top) and heterozygous/mixed clonality (middle) guanine to thymine substitution (arrow) in exon 12 of JAK2 in granulocyte genomic DNA from 2 patients with MDS. The predicted protein consequence is substitution of phenyalanine for valine at position 617 of NP_004 963. The bottom chromatogram is the wild-type sequence.   PCR products were cleaned with the QIAquick PCR purification Kit (Qiagen, Valencia, CA). Fluorescent dye chemistry sequencing was performed using the same primers used for amplification, on an ABI PRISM 3700 DNA Analyzer (Applied Biosystems, Foster City, CA). Sequencher 4.2 (Gene Codes, Ann Arbor, MI) and GenBank Accession NM_004 972 (JAK2 mRNA) and the corresponding region from the NC_000 009 chromosome 9 contig were used for sequence analysis.    Results and discussion Top Abstract Introduction Study design Results and discussion References   The 50 normal samples were all wild type for exon 12 of JAK2. Only 3 JAK2 V617F mutations were detected among 119 CMML samples; all 3 sequence chromatograms displayed peaks from both wild-type and mutant genomic DNA at the locus of interest (Figure 1). Since JAK2 is encoded by an autosomal gene, when 2 chromatogram peaks are present in a particular DNA sample, this finding may represent a heterozygous mutation, or DNA derived from an admixture of clonal and residual normal hematopoietic elements.15 Some patients with CMML have primarily myelodysplastic features (eg, ineffective hematopoiesis and cytologic dysplasia) and others have more myeloproliferative features (eg, leukocytosis and splenomegaly).16-19 Appropriate classification of these patients has been controversial for many years. Attempts to separate CMML into dysplastic and proliferative subtypes using a peripheral white blood count (WBC) of 13 x 109/L as a cutoff have been widely challenged, because WBC alone is not a sensitive or specific marker for proliferative/dysplastic features.20,21 The 1982 French-American-British MDS classification incorporated CMML,22 but the most recent World Health Organization classification of myeloid neoplasia places CMML in a distinct myeloproliferative-myelodysplastic overlap category.14 The fact that CMML is defined principally by an arbitrary peripheral blood monocytosis threshold limits clinicians' ability to offer a prognosis on the basis of disease subtype alone. A specific molecular lesion might aid nosology and prognostication, but this study demonstrates that JAK2 V617F is not useful for these purposes. Among the 3 patients with CMML in this study with mutations, one had primarily proliferative features, one was primarily dysplastic, and the third was mixed; 2 of the 3 had mild to moderate marrow reticulin fibrosis, compared with 22 of 119 (18%) with 1+ and 2+ fibrosis in the series as a whole. JAK2 V617F was detected in 5 of 101 MDS samples: 1 was homozygous (ie, no wild-type DNA detected; Figure 1) and 4 had heterozygous/mixed clonality mutations. One of these patients had insufficient metaphases for cytogenetic analysis whereas the other 4 had normal karyotypes. There were no distinguishing clinical or pathologic features among these patients: moderate marrow fibrosis was present in 1 individual, but proliferative features including leukocytosis and hepatosplenomegaly were not present. Marrow fibrosis was not present in other cases. With respect to MDS subtype, 2 had refractory anemia and ringed sideroblasts (RARS), 1 had refractory cytopenia with multilineage dysplasia (RCMD), 1 had refractory anemia (RA), and 1 had refractory anemia with excess of blasts 1 (RAEB-1). The JAK2 mutation was not detected in 11 patients with HES, and was found in only 2 of 8 SM samples. In addition to mastocytosis, one of these 2 patients with SM had monocytosis and moderate reticulin fibrosis in the marrow, consistent with underlying CMML. The patient also had a history of B-cell lymphoma. The 2 patients with JAK2 V617F both lacked the D816V c-KIT mutation; 2 other patients in the series who had the c-KIT mutation did not have the JAK2 mutation. True CNL is extremely rare23 and only 6 DNA samples were available for analysis; one of these had a homozygous JAK2 V617F mutation. Both peripheral blood mononuclear cell and granulocyte samples were also available from this patient, and mutant JAK2 was exclusively present in both samples, suggesting either complete replacement of the marrow by a clone bearing the mutation or a germ line mutation (buccal cells or fibroblasts were not available for comparison). Interestingly, this patient, as was the case with the single mutation–positive patient with SM, also had a history of B-cell lymphoma. Regardless, the patient continued to do well on oral hydroxyurea therapy, more than 2 years from initial diagnosis of CNL. Future analyses might include more CNL samples to better assess the true JAK2 mutation rate, as well as DNA from other rare CMD subtypes such as chronic basophilic leukemia and juvenile myelomonocytic leukemia. It will also be of interest to separate out various hematopoietic lineages including lymphocytes from patients with CMD with JAK2 V617F mutations, to assess the clonality and lineage specificity of this finding in a more rigorous fashion. In conclusion, while the JAK2 V617F mutation is extraordinarily common in classic BCR/ABL-negative MPDs, it appears to be rare in both MDS and the aCMD subtypes analyzed here, with the possible exception of CNL. The aberrant proliferative signal in these other cases remains mysterious. Future investigations might focus on other molecules in the same signaling pathway as JAK2,24 or on other parallel signal transduction cascades. Meanwhile, it may also be of interest to search for activating JAK2 mutations in acute leukemia samples (especially erythroleukemia, given the high mutation prevalence in PV) and in other neoplasms. Given the history of lymphoma in a subset of patients with the JAK2 mutation in this series, the potential for involvement of the JAK–signal transducers and activators of transcription (STAT) signaling pathway or its negative regulators (eg, suppressor of cytokine signaling-1, Src homology 2–containing protein tyrosine phosphatase-1 [SHP-1], SHP-2) in lymphoproliferative disorders should also be investigated.    Footnotes   Submitted March 23, 2005; accepted April 25, 2005. Prepublished online as Blood First Edition Paper, April 28, 2005; DOI 10.1182/blood-2005-03-1183. Supported by National Institutes of Health grant K12 CA 90 628 (D.P.S.). The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734. Reprints: Ayalew Tefferi, Mayo Clinic, 200 First Street SW, Rochester MN 55905; e-mail: tefferi.ayalew{at}mayo.edu.    References Top Abstract Introduction Study design Results and discussion References   Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365: 1054-1061.[Medline] [Order article via Infotrieve] Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and agnogenic myeloid metaplasia. Cancer Cell. 2005; 7: 387-397.[CrossRef][Medline] [Order article via Infotrieve] James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 484: 1144-1148. Kralovics R, Passamonti F, Buser A, et al. A gain-of-function mutation of Jak2 in myeloproliferative disorders. N Engl J Med. 2005;352: 1779-1790.[Abstract/Free Full Text] Tefferi A. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview. Mayo Clin Proc. 1998;73: 1177-1184.[Abstract] Tefferi A. Chronic myeloid disorders: classification and treatment overview. Semin Hematol. 2001; 38: 1-4.[Medline] [Order article via Infotrieve] Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med. 2002;347: 481-487.[Abstract/Free Full Text] Pardanani A, Brockman SR, Paternoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104: 3038-3045.[Abstract/Free Full Text] Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet. 2003;362: 535-536.[CrossRef][Medline] [Order article via Infotrieve] Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344: 1031-1037.[Abstract/Free Full Text] O'Hare T, Walters DK, Deininger MW, Druker BJ. AMN101: tightening the grip of imatinib. Cancer Cell. 2005;7: 117-119.[CrossRef][Medline] [Order article via Infotrieve] Sawyers CL, Shah NP, Kantarjian HM, et al. Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalation study. Plenary session, 46th Annual Meeting of the American Society of Hematology. San Diego, CA; 2004. Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood. 2005;105: 443-452.[Abstract/Free Full Text] Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17: 3835-3849.[Abstract/Free Full Text] Boultwood J, Wainscoat JS. Clonality in the myelodysplastic syndromes. Int J Hematol. 2001;73: 411-415.[Medline] [Order article via Infotrieve] Onida F, Beran M. Chronic myelomonocytic leukemia: myeloproliferative variant. Curr Hematol Rep. 2004;3: 218-226.[Medline] [Order article via Infotrieve] Cortes J. CMML: a biologically distinct myeloproliferative disease. Curr Hematol Rep. 2003;2: 202-208.[Medline] [Order article via Infotrieve] Gonzalez-Medina I, Bueno J, Torrequebrada A, Lopez A, Vallespi T, Massague I. Two groups of chronic myelomonocytic leukaemia, myelodysplastic and myeloproliferative: prognostic implications in a series of a single center. Leuk Res. 2002;26: 821-824.[CrossRef][Medline] [Order article via Infotrieve] Nosslinger T, Reisner R, Gruner H, et al. Dysplastic versus proliferative CMML: a retrospective analysis of 91 patients from a single institution. Leuk Res. 2001;25: 741-747.[CrossRef][Medline] [Order article via Infotrieve] Germing U, Gattermann N, Minning H, Heyll A, Aul C. Problems in the classification of CMML: dysplastic versus proliferative type. Leuk Res. 1998;22: 871-878.[CrossRef][Medline] [Order article via Infotrieve] Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27: 95-120.[CrossRef][Medline] [Order article via Infotrieve] Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51: 189-199.[Medline] [Order article via Infotrieve] Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature. Leukemia. 2005;19: 313-317.[CrossRef][Medline] [Order article via Infotrieve] Sandberg EM, Wallace TA, Godeny MD, Vonderlinden D, Sayeski PP. Jak2 tyrosine kinase: a true jak of all trades? Cell Biochem Biophys. 2004;41: 207-232.[CrossRef][Medline] [Order article via Infotrieve] CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: JAK2 V617F and ringed sideroblasts: not necessarily RARS-T David P. Steensma and Ayalew Tefferi Blood 2008 111: 1748. [Full Text] [PDF] Related Letters in Blood Online: A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples Martin Sattler, Christoph Walz, Brian J. Crowley, Eva Lengfelder, Pasi A. Jänne, Andrew M. Rogers, Yanan Kuang, Robert J. Distel, Andreas Reiter, and James D. Griffin Blood 2006 107: 1237-1238. [Full Text] [PDF] Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7 Stefan Fröhling, Daniel B. Lipka, Sabine Kayser, Claudia Scholl, Richard F. Schlenk, Hartmut Döhner, D. Gary Gilliland, Ross L. Levine, and Konstanze Döhner Blood 2006 107: 1242-1243. [Full Text] [PDF] This article has been cited by other articles: A. Tefferi and J. W. Vardiman Myelodysplastic Syndromes N. Engl. J. Med., November 5, 2009; 361(19): 1872 - 1885. [Full Text] [PDF] M. Cankovic, L. Whiteley, R. C. Hawley, R. J. Zarbo, and D. Chitale Clinical Performance of JAK2 V617F Mutation Detection Assays in a Molecular Diagnostics Laboratory: Evaluation of Screening and Quantitation Methods Am J Clin Pathol, November 1, 2009; 132(5): 713 - 721. [Abstract] [Full Text] [PDF] A Pich, L Riera, F Sismondi, L Godio, L D. Bonino, F Marmont, and P F. di Celle JAK2V617F activating mutation is associated with the myeloproliferative type of chronic myelomonocytic leukaemia J. Clin. Pathol., September 1, 2009; 62(9): 798 - 801. [Abstract] [Full Text] [PDF] J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes Blood, July 30, 2009; 114(5): 937 - 951. [Abstract] [Full Text] [PDF] I. Rapado, S. Grande, E. Albizua, R. Ayala, J.-A. Hernandez, M. Gallardo, F. Gilsanz, and J. Martinez-Lopez High Resolution Melting Analysis for JAK2 Exon 14 and Exon 12 Mutations: A Diagnostic Tool for Myeloproliferative Neoplasms J. Mol. Diagn., March 1, 2009; 11(2): 155 - 161. [Abstract] [Full Text] [PDF] J. Malysz and D. Crisan Correlation of JAK2 V617F Mutant Allele Quantitation with Clinical Presentation and Type of Chronic Myeloproliferative Neoplasm Ann. Clin. Lab. Sci., January 1, 2009; 39(4): 345 - 350. [Abstract] [Full Text] [PDF] R. L. Levine and D. G. Gilliland Myeloproliferative disorders Blood, September 15, 2008; 112(6): 2190 - 2198. [Abstract] [Full Text] [PDF] H. Bruchova, M. Merkerova, and J. T. Prchal Aberrant expression of microRNA in polycythemia vera Haematologica, July 1, 2008; 93(7): 1009 - 1016. [Abstract] [Full Text] [PDF] S. Xing, T. H. Wanting, W. Zhao, J. Ma, S. Wang, X. Xu, Q. Li, X. Fu, M. Xu, and Z. J. Zhao Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice Blood, May 15, 2008; 111(10): 5109 - 5117. [Abstract] [Full Text] [PDF] G. Wernig, J. R. Gonneville, B. J. Crowley, M. S. Rodrigues, M. M. Reddy, H. E. Hudon, C. Walz, A. Reiter, K. Podar, Y. Royer, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes Blood, April 1, 2008; 111(7): 3751 - 3759. [Abstract] [Full Text] [PDF] D. P. Steensma and A. Tefferi JAK2 V617F and ringed sideroblasts: not necessarily RARS-T Blood, February 1, 2008; 111(3): 1748 - 1748. [Full Text] [PDF] A. H. Schmitt-Graeff, S.-S. Teo, M. Olschewski, F. Schaub, S. Haxelmans, A. Kirn, P. Reinecke, U. Germing, and R. C. Skoda JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis Haematologica, January 1, 2008; 93(1): 34 - 40. [Abstract] [Full Text] [PDF] K. L. Wu, H. Miao, and S. Khan JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1836 - F1846. [Abstract] [Full Text] [PDF] A. Pradhan, Q. T. Lambert, and G. W. Reuther Transformation of hematopoietic cells and activation of JAK2-V617F by IL-27R, a component of a heterodimeric type I cytokine receptor PNAS, November 20, 2007; 104(47): 18502 - 18507. [Abstract] [Full Text] [PDF] N. Paffett-Lugassy, N. Hsia, P. G. Fraenkel, B. Paw, I. Leshinsky, B. Barut, N. Bahary, J. Caro, R. Handin, and L. I. Zon Functional conservation of erythropoietin signaling in zebrafish Blood, October 1, 2007; 110(7): 2718 - 2726. [Abstract] [Full Text] [PDF] A. Tefferi, J. Thiele, A. Orazi, H. M. Kvasnicka, T. Barbui, C. A. Hanson, G. Barosi, S. Verstovsek, G. Birgegard, R. Mesa, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel Blood, August 15, 2007; 110(4): 1092 - 1097. [Abstract] [Full Text] [PDF] A. M. Vannucchi, E. Antonioli, P. Guglielmelli, A. Rambaldi, G. Barosi, R. Marchioli, R. M. Marfisi, G. Finazzi, V. Guerini, F. Fabris, et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia Blood, August 1, 2007; 110(3): 840 - 846. [Abstract] [Full Text] [PDF] A. Theocharides, M. Boissinot, F. Girodon, R. Garand, S.-S. Teo, E. Lippert, P. Talmant, A. Tichelli, S. Hermouet, and R. C. Skoda Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood, July 1, 2007; 110(1): 375 - 379. [Abstract] [Full Text] [PDF] A. Tefferi and A. Pardanani Evaluation of 'Increased' Hemoglobin in the JAK2 Mutations Era: A Diagnostic Algorithm Based on Genetic Tests Mayo Clin. Proc., May 1, 2007; 82(5): 599 - 604. [Abstract] [Full Text] [PDF] L. Teofili, F. Giona, M. Martini, T. Cenci, F. Guidi, L. Torti, G. Palumbo, A. Amendola, R. Foa, and L. M. Larocca Markers of Myeloproliferative Diseases in Childhood Polycythemia Vera and Essential Thrombocythemia J. Clin. Oncol., March 20, 2007; 25(9): 1048 - 1053. [Abstract] [Full Text] [PDF] S. Malinge, R. Ben-Abdelali, C. Settegrana, I. Radford-Weiss, M. Debre, K. Beldjord, E. A. Macintyre, J.-L. Villeval, W. Vainchenker, R. Berger, et al. Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia Blood, March 1, 2007; 109(5): 2202 - 2204. [Abstract] [Full Text] [PDF] Z. Li, M. Xu, S. Xing, W. T. Ho, T. Ishii, Q. Li, X. Fu, and Z. J. Zhao Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth J. Biol. Chem., February 9, 2007; 282(6): 3428 - 3432. [Abstract] [Full Text] [PDF] L. M. Scott, W. Tong, R. L. Levine, M. A. Scott, P. A. Beer, M. R. Stratton, P. A. Futreal, W. N. Erber, M. F. McMullin, C. N. Harrison, et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis N. Engl. J. Med., February 1, 2007; 356(5): 459 - 468. [Abstract] [Full Text] [PDF] N. Gattermann, J. Billiet, R. Kronenwett, E. Zipperer, U. Germing, F. Nollet, A. Criel, and D. Selleslag High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count > 600 x 109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable Blood, February 1, 2007; 109(3): 1334 - 1335. [Full Text] [PDF] X. Xu, Q. Zhang, J. Luo, S. Xing, Q. Li, S. B. Krantz, X. Fu, and Z. J. Zhao JAK2V617F: prevalence in a large Chinese hospital population Blood, January 1, 2007; 109(1): 339 - 342. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF] T. G.P. Bumm, C. Elsea, A. S. Corbin, M. Loriaux, D. Sherbenou, L. Wood, J. Deininger, R. T. Silver, B. J. Druker, and M. W.N. Deininger Characterization of Murine JAK2V617F-Positive Myeloproliferative Disease Cancer Res., December 1, 2006; 66(23): 11156 - 11165. [Abstract] [Full Text] [PDF] A. D. Pardanani, R. L. Levine, T. Lasho, Y. Pikman, R. A. Mesa, M. Wadleigh, D. P. Steensma, M. A. Elliott, A. P. Wolanskyj, W. J. Hogan, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood, November 15, 2006; 108(10): 3472 - 3476. [Abstract] [Full Text] [PDF] P. J. Campbell, E. J. Baxter, P. A. Beer, L. M. Scott, A. J. Bench, B. J. P. Huntly, W. N. Erber, R. Kusec, T. S. Larsen, S. Giraudier, et al. Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation Blood, November 15, 2006; 108(10): 3548 - 3555. [Abstract] [Full Text] [PDF] H. Szpurka, R. Tiu, G. Murugesan, S. Aboudola, E. D. Hsi, K. S. Theil, M. A. Sekeres, and J. P. Maciejewski Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation Blood, October 1, 2006; 108(7): 2173 - 2181. [Abstract] [Full Text] [PDF] D. P. Steensma JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2006; 8(4): 397 - 411. [Abstract] [Full Text] [PDF] M. Boissinot, R. Garand, M. Hamidou, and S. Hermouet The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood, September 1, 2006; 108(5): 1781 - 1782. [Full Text] [PDF] A. Tefferi, J. Cortes, S. Verstovsek, R. A. Mesa, D. Thomas, T. L. Lasho, W. J. Hogan, M. R. Litzow, J. B. Allred, D. Jones, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia Blood, August 15, 2006; 108(4): 1158 - 1164. [Abstract] [Full Text] [PDF] T. Horn, M. Kremer, T. Dechow, W. M. Pfeifer, B. Geist, M. Perker, J. Duyster, L. Quintanilla-Martinez, and F. Fend Detection of the Activating JAK2 V617F Mutation in Paraffin-Embedded Trephine Bone Marrow Biopsies of Patients with Chronic Myeloproliferative Diseases J. Mol. Diagn., July 1, 2006; 8(3): 299 - 304. [Abstract] [Full Text] [PDF] C. Walz, B. J. Crowley, H. E. Hudon, J. L. Gramlich, D. S. Neuberg, K. Podar, J. D. Griffin, and M. Sattler Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition J. Biol. Chem., June 30, 2006; 281(26): 18177 - 18183. [Abstract] [Full Text] [PDF] A. I. Schafer Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia Blood, June 1, 2006; 107(11): 4214 - 4222. [Abstract] [Full Text] [PDF] O. Bock, G. Busche, C. Koop, S. Schroter, T. Buhr, and H. Kreipe Detection of the Single Hotspot Mutation in the JH2 Pseudokinase Domain of Janus Kinase 2 in Bone Marrow Trephine Biopsies Derived from Chronic Myeloproliferative Disorders J. Mol. Diagn., May 1, 2006; 8(2): 170 - 177. [Abstract] [Full Text] [PDF] U. Popat, A. Frost, E. Liu, Y. Guan, A. Durette, V. Reddy, and J. T. Prchal High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension Blood, May 1, 2006; 107(9): 3486 - 3488. [Abstract] [Full Text] [PDF] C. H. M. Jamieson, J. Gotlib, J. A. Durocher, M. P. Chao, M. R. Mariappan, M. Lay, C. Jones, J. L. Zehnder, S. L. Lilleberg, and I. L. Weissman The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation PNAS, April 18, 2006; 103(16): 6224 - 6229. [Abstract] [Full Text] [PDF] A. Tefferi, M. A. Elliott, and A. Pardanani Atypical Myeloproliferative Disorders: Diagnosis and Management Mayo Clin. Proc., April 1, 2006; 81(4): 553 - 563. [Abstract] [Full Text] [PDF] D. P. Steensma, A. Pardanani, W. S. Stevenson, R. Hoyt, H. Kiu, A. P. Grigg, J. Szer, S. Juneja, D. J. Hilton, W. S. Alexander, et al. More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders Blood, February 15, 2006; 107(4): 1733 - 1735. [Full Text] [PDF] A. P. Wolanskyj, S. M. Schwager, R. F. McClure, D. R. Larson, and A. Tefferi Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors Mayo Clin. Proc., February 1, 2006; 81(2): 159 - 166. [Abstract] [Full Text] [PDF] M. Sattler, C. Walz, B. J. Crowley, E. Lengfelder, P. A. Janne, A. M. Rogers, Y. Kuang, R. J. Distel, A. Reiter, and J. D. Griffin A sensitive high-throughput method to detect activating mutations of Jak2 in peripheral-blood samples Blood, February 1, 2006; 107(3): 1237 - 1238. [Full Text] [PDF] S. Frohling, D. B. Lipka, S. Kayser, C. Scholl, R. F. Schlenk, H. Dohner, D. G. Gilliland, R. L. Levine, and K. Dohner Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7 Blood, February 1, 2006; 107(3): 1242 - 1243. [Full Text] [PDF] R. L. Levine and G. Wernig Role of JAK-STAT Signaling in the Pathogenesis of Myeloproliferative Disorders Hematology, January 1, 2006; 2006(1): 233 - 239. [Abstract] [Full Text] [PDF] A. Tefferi Classification, Diagnosis and Management of Myeloproliferative Disorders in the JAK2V617F Era Hematology, January 1, 2006; 2006(1): 240 - 245. [Abstract] [Full Text] [PDF] A. Tefferi V617F "JAKs" up myeloproliferative signal Blood, November 15, 2005; 106(10): 3335 - 3336. [Full Text] [PDF] J. Jelinek, Y. Oki, V. Gharibyan, C. Bueso-Ramos, J. T. Prchal, S. Verstovsek, M. Beran, E. Estey, H. M. Kantarjian, and J.-P. J. Issa JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia Blood, November 15, 2005; 106(10): 3370 - 3373. [Abstract] [Full Text] [PDF] R. L. Levine, M. Loriaux, B. J. P. Huntly, M. L. Loh, M. Beran, E. Stoffregen, R. Berger, J. J. Clark, S. G. Willis, K. T. Nguyen, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia Blood, November 15, 2005; 106(10): 3377 - 3379. [Abstract] [Full Text] [PDF] J. D. Licht and D. W. Sternberg The Molecular Pathology of Acute Myeloid Leukemia Hematology, January 1, 2005; 2005(1): 137 - 142. [Abstract] [Full Text] [PDF] A. T. Look Molecular Pathogenesis of MDS Hematology, January 1, 2005; 2005(1): 156 - 160. [Abstract] [Full Text] [PDF] W. Vainchenker and S. N. Constantinescu A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases Hematology, January 1, 2005; 2005(1): 195 - 200. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) All Versions of this Article: 2005-03-1183v1 106/4/1207    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Steensma, D. P. Articles by Tefferi, A. Search for Related Content PubMed PubMed Citation Articles by Steensma, D. P. Articles by Tefferi, A. Related Collections Neoplasia Oncogenes and Tumor Suppressors Brief Reports Clinical Trials and Observations Related Article in Blood Online Related Letters in Blood Online Social Bookmarking                   What's this?

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020